Cargando…
Spironolactone in cardiovascular disease: an expanding universe?
Spironolactone has been marketed for over half a century as a ‘potassium-sparing diuretic’, used primarily in patients with ascites. With the realization that primary aldosteronism is the most common (5-13%) form of secondary hypertension, it has become widely used as a mineralocorticoid receptor an...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000Research
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615771/ https://www.ncbi.nlm.nih.gov/pubmed/29034087 http://dx.doi.org/10.12688/f1000research.11887.1 |